Base de dados : MEDLINE
Pesquisa : C10.114.750 [Categoria DeCS]
Referências encontradas : 3686 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 369 ir para página                         

  1 / 3686 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463414
[Au] Autor:Laws EJ; Harcourt-Brown TR; Granger N; Rose JH
[Ad] Endereço:School of Veterinary Sciences, University of Bristol, Langford Small Animal Hospital, Bristol, BS405DU, UK.
[Ti] Título:An exploratory study into factors influencing development of acute canine polyradiculoneuritis in the UK.
[So] Source:J Small Anim Pract;58(8):437-443, 2017 Aug.
[Is] ISSN:1748-5827
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To investigate whether the development of acute canine polyradiculoneuritis is associated with various putative risk factors. MATERIALS AND METHODS: Retrospective case-control study with conditional logistic regression analysis from a referral hospital population in the UK where controls were matched for year of presentation. RESULTS: Forty-three cases were identified with acute canine polyradiculoneuritis and 86 controls were selected. Jack Russell terriers and West Highland white terriers were found to have a significantly greater odds of developing acute canine polyradiculoneuritis compared to a mixed baseline group of dogs. The odds of developing acute canine polyradiculoneuritis were greater in the autumn and winter compared to spring. Vaccination, rural/urban habitation, sex, neuter status and age were not associated with development of acute canine polyradiculoneuritis in our population of dogs. CLINICAL SIGNIFICANCE: Breed and season were associated with development of acute canine polyradiculoneuritis. However, this is a small sample and so this observation needs confirmation in further studies and other factors may also be involved. Nevertheless, these findings may be important in further understanding the aetiopathogenesis of this condition.
[Mh] Termos MeSH primário: Doenças do Cão/epidemiologia
Polirradiculoneuropatia/veterinária
[Mh] Termos MeSH secundário: Animais
Cruzamento
Estudos de Casos e Controles
Cães
Feminino
Masculino
Polirradiculoneuropatia/epidemiologia
Estudos Retrospectivos
Fatores de Risco
Estações do Ano
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1111/jsap.12683


  2 / 3686 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28603207
[Au] Autor:Okiyama N; Tanaka R
[Ad] Endereço:Department of Dermatology, Faculty of Medicine, University of Tsukuba.
[Ti] Título:Varied immuno-related adverse events induced by immune-check point inhibitors - Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6.
[So] Source:Nihon Rinsho Meneki Gakkai Kaishi;40(2):95-101, 2017.
[Is] ISSN:1349-7413
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:Nivolumab is a standard recombinant antibody treatment for patients with malignant melanoma (MM), which functions as an immune checkpoint inhibitor by blocking the programmed cell death-1 (PD-1) pathway in T cells. However, it leads to various immune-related adverse events (irAEs), and also exacerbates underlying autoimmune diseases. Herein we report cases of MM with irAE. Case 1: A 69-year-old woman with MM developed destructive thyroiditis resulting in hypothyroidism after 3 doses of nivolumab, and had been treated with thyroid gland auxiliary therapy. Case 2: A 80-year-old man with MM developed an acute onset of hyperthyroidism after 4 doses of nivolumab. Case 3: A 85-year-old woman with MM developed polyradiculoneuropathy resulting in somatosensory disorder and muscle weakness after 2 doses of nivolumab, and had been treated with intravenous immunoglobulin and oral predonisolone (40 mg/day). Case 4: A 77-year-old man with MM developed psoriasiform dermatitis after local injections of IFN-ß and 11 doses of nivolumab. Case 5: Case 2 also developed psoriasiform dermatitis. We analyzed serum levels of inflammatory cytokines in MM patients before/after treatments with nivolumab. All six patients who developed psoriasiform dermatitis with/without anamnesis of psoriasis after treatment with nivolumab, and all seven patients with other irAE exhibited increased serum IL-6 levels after nivolumab treatment, while decreased serum levels of IL-6 were observed in 5 of 7 non-afflicted MM patients. In addition, MM patients who achieved good responses to nivolumab significantly exhibited decreased serum TNF-α levels after nivolumab treatment compared to progressive MM patients.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/efeitos adversos
Dermatite/etiologia
Interleucina-6/sangue
Psoríase/etiologia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Anticorpos Monoclonais/uso terapêutico
Dermatite/sangue
Feminino
Seres Humanos
Hipertireoidismo/sangue
Hipertireoidismo/etiologia
Masculino
Melanoma/tratamento farmacológico
Polirradiculoneuropatia/sangue
Polirradiculoneuropatia/etiologia
Receptor de Morte Celular Programada 1/imunologia
Psoríase/sangue
Linfócitos T/imunologia
Tireoidite/sangue
Tireoidite/etiologia
Fator de Necrose Tumoral alfa/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (IL6 protein, human); 0 (Interleukin-6); 0 (PDCD1 protein, human); 0 (Programmed Cell Death 1 Receptor); 0 (Tumor Necrosis Factor-alpha); 31YO63LBSN (nivolumab)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171015
[Lr] Data última revisão:
171015
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170613
[St] Status:MEDLINE
[do] DOI:10.2177/jsci.40.95


  3 / 3686 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28100408
[Au] Autor:Kimura A; Takemura M; Saito K; Serrero G; Yoshikura N; Hayashi Y; Inuzuka T
[Ad] Endereço:Department of Neurology and Geriatrics, Gifu University Graduate School of Medicine, Gifu, Japan. Electronic address: kimura1@gifu-u.ac.jp.
[Ti] Título:Increased cerebrospinal fluid progranulin correlates with interleukin-6 in the acute phase of neuromyelitis optica spectrum disorder.
[So] Source:J Neuroimmunol;305:175-181, 2017 Apr 15.
[Is] ISSN:1872-8421
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:We examined progranulin (PGRN) levels in cerebrospinal fluid (CSF) samples during the acute phase in 15 patients with neuromyelitis optica spectrum disorders (NMOSD) and compared the results with those from 17 patients with multiple sclerosis (MS), 30 patients with other inflammatory neurological diseases (OIND), and 20 non-inflammatory controls (NIC). CSF PGRN levels of NMOSD patients were significantly higher than those of MS patients and NICs. These levels correlated with CSF interleukin-6 levels, CSF cell counts, CSF protein levels, improvements in the Expanded Disability Status Scale score, and affected total spinal cord lesion length in the NMOSD patients.
[Mh] Termos MeSH primário: Peptídeos e Proteínas de Sinalização Intercelular/líquido cefalorraquidiano
Neuromielite Óptica/líquido cefalorraquidiano
[Mh] Termos MeSH secundário: Adulto
Idoso
Anticorpos/sangue
Aquaporina 4/imunologia
Avaliação da Deficiência
Feminino
Seguimentos
Seres Humanos
Interleucina-6/líquido cefalorraquidiano
Masculino
Meia-Idade
Esclerose Múltipla/líquido cefalorraquidiano
Polirradiculoneuropatia/líquido cefalorraquidiano
Estatística como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (AQP4 protein, human); 0 (Antibodies); 0 (Aquaporin 4); 0 (GRN protein, human); 0 (Intercellular Signaling Peptides and Proteins); 0 (Interleukin-6)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170120
[St] Status:MEDLINE


  4 / 3686 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:27568864
[Au] Autor:Mevorach D; Reiner I; Grau A; Ilan U; Berkun Y; Ta-Shma A; Elpeleg O; Shorer Z; Edvardson S; Tabib A
[Ad] Endereço:Rheumatology Research Center and Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
[Ti] Título:Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation.
[So] Source:Ann Neurol;80(5):708-717, 2016 Nov.
[Is] ISSN:1531-8249
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The objective of this work was to report on the outcome of eculizumab treatment in pediatric patients with recurrent acute predominantly motor, demyelinating neuropathy with conduction block, and chronic hemolysis attributed to p.Cys89Tyr mutation in the CD59 gene. METHODS: Four patients were recruited from our new registry of patients with homozygosity for the p.Cys89Tyr mutation on CD59. Participants received repeated intravenous eculizumab. In this 24-month open-label phase IIa study, we aimed to determine whether eculizumab reduces chronic hemolysis, and cumulative doses of steroids and intravenous immunoglobulin (IVIG), and ameliorates neurological deficits, compared to pretreatment status. Treatment response was evaluated every 2 to 4 weeks over 104 weeks and included examination with gross motor scoring by American Spinal Injury Association Impairment Scale and Inflammatory Neuropathy Cause and Treatment disability score, laboratory examination, well-being [12-item Short Form Health Survey; SF-12]). Neurological relapses and cumulative dose of IVIGs and/or corticosteroids before and after treatment were documented. Red blood cells (RBCs) and neutrophils were stained to evaluate C5b-9 deposition. ClinicalTrials.gov: NCT01579838. RESULTS: Dramatic and significant neurological amelioration in the upper limbs and trunk with more-modest amelioration in the lower limbs was observed in all patients. Corticosteroid and IVIG treatment was completely stopped. No patient relapsed during treatment despite infections, and there were no hospital admissions. Decreased C3bi and C5b-9 deposition on RBCs and neutrophils was documented (p < 0.0001). The SF-12 health questionnaires indicated significant improvement (p < 0.003). INTERPRETATION: Eculizumab was safely administered to these patients. Marked clinical improvement suggests that eculizumab may be a life-saving treatment for patients with acute predominantly motor, demyelinating neuropathy with conduction block, and secondary axonal damage attributed to primary p.Cys89Tyr mutation in the CD59 gene. Ann Neurol 2016;80:708-717.
[Mh] Termos MeSH primário: Anemia Hemolítica/complicações
Anticorpos Monoclonais Humanizados/farmacologia
Antígenos CD59/genética
Hemoglobinúria/complicações
Hemólise/efeitos dos fármacos
Polirradiculoneuropatia
Sistema de Registros
[Mh] Termos MeSH secundário: Anticorpos Monoclonais Humanizados/administração & dosagem
Pré-Escolar
Feminino
Seres Humanos
Lactente
Masculino
Mutação
Polirradiculoneuropatia/tratamento farmacológico
Polirradiculoneuropatia/etiologia
Polirradiculoneuropatia/fisiopatologia
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Humanized); 0 (CD59 Antigens); 101754-01-2 (CD59 protein, human); A3ULP0F556 (eculizumab)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160830
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1002/ana.24770


  5 / 3686 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27470489
[Au] Autor:Sicello M; Sevy A; Borentain P; Gérolami R; Attarian S; Colson P
[Ad] Endereço:Institut Hospitalo-Universitaire (IHU) Méditerranée Infection, Assistance Publique-Hôpitaux de Marseille, Centre Hospitalo-Universitaire Timone, Pôle des Maladies Infectieuses et Tropicales Clinique et Biologique, Fédération de Bactériologie-Hygiène-Virologie, 264 rue Saint-Pierre, 13385 Marseille C
[Ti] Título:Evolution of hepatitis E virus-associated meningo-polyradiculoneuropathy on ribavirin.
[So] Source:Int J Antimicrob Agents;48(3):343-5, 2016 Sep.
[Is] ISSN:1872-7913
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Mh] Termos MeSH primário: Antivirais/administração & dosagem
Hepatite E/complicações
Hepatite E/tratamento farmacológico
Meningite/tratamento farmacológico
Polirradiculoneuropatia/tratamento farmacológico
Ribavirina/administração & dosagem
[Mh] Termos MeSH secundário: Líquido Cefalorraquidiano/virologia
Hepatite E/patologia
Hepatite E/virologia
Vírus da Hepatite E/isolamento & purificação
Seres Humanos
Masculino
Meningite/patologia
Meningite/virologia
Meia-Idade
Polirradiculoneuropatia/patologia
Polirradiculoneuropatia/virologia
RNA Viral/isolamento & purificação
Soro/virologia
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Antiviral Agents); 0 (RNA, Viral); 49717AWG6K (Ribavirin)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170306
[Lr] Data última revisão:
170306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160730
[St] Status:MEDLINE


  6 / 3686 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27468083
[Au] Autor:de Maleissye MF; Nicolas G; Saiag P
[Ad] Endereço:Université Versailles Saint-Quentin-en-Yvelines, Versailles, France philippe.saiag@uvsq.fr.
[Ti] Título:Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy.
[So] Source:N Engl J Med;375(3):296-7, 2016 Jul 21.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados/efeitos adversos
Antineoplásicos/efeitos adversos
Polirradiculoneuropatia/induzido quimicamente
[Mh] Termos MeSH secundário: Potenciais de Ação
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Melanoma/tratamento farmacológico
Meia-Idade
Músculo Esquelético/efeitos dos fármacos
Músculo Esquelético/fisiopatologia
Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/induzido quimicamente
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Humanized); 0 (Antineoplastic Agents); DPT0O3T46P (pembrolizumab)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:160729
[Lr] Data última revisão:
160729
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160729
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1515584


  7 / 3686 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27251375
[Au] Autor:Liewluck T; Engelstad JK; Mauermann ML
[Ad] Endereço:Department of Neurology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA. liewluck.teerin@mayo.edu.
[Ti] Título:Immunotherapy-responsive allodynia due to distal acquired demyelinating symmetric (DADS) neuropathy.
[So] Source:Muscle Nerve;54(5):973-977, 2016 Nov.
[Is] ISSN:1097-4598
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Distal acquired demyelinating symmetric (DADS) neuropathy is a distal variant of chronic inflammatory demyelinating polyradiculoneuropathy. It is characterized by chronic distal symmetric sensory or sensorimotor deficits. Sensory ataxia is a common clinical presentation. Nerve conduction studies typically show markedly prolonged distal motor latencies. METHODS: We report 2 patients with chronic progressive generalized pain and fatigue, with normal neurological examinations except for allodynia. RESULTS: Nerve conduction studies were typical of DADS neuropathy. Monoclonal protein studies were negative. Cerebrospinal fluid protein levels were elevated. Sural nerve biopsies revealed segmental demyelination and remyelination. One biopsy had marked endoneurial and epineurial lymphocytic infiltration. Immunomodulatory therapy alleviated the pain and fatigue and markedly improved distal motor latencies in both patients. CONCLUSIONS: DADS neuropathy can present with pain and a normal neurological examination apart from allodynia. Nerve conduction studies are necessary for diagnosis. These patients respond to immunotherapy better than typical DADS neuropathy patients with sensory ataxia. Muscle Nerve 54: 973-977, 2016.
[Mh] Termos MeSH primário: Doenças Desmielinizantes/terapia
Imunoterapia/métodos
Polirradiculoneuropatia/imunologia
Polirradiculoneuropatia/terapia
[Mh] Termos MeSH secundário: Adulto
Doenças Desmielinizantes/complicações
Feminino
Seres Humanos
Meia-Idade
Fibras Nervosas/patologia
Fibras Nervosas/ultraestrutura
Condução Nervosa/fisiologia
Polirradiculoneuropatia/complicações
Polirradiculoneuropatia/patologia
[Pt] Tipo de publicação:CASE REPORTS
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170629
[Lr] Data última revisão:
170629
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160603
[St] Status:MEDLINE
[do] DOI:10.1002/mus.25206


  8 / 3686 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27175564
[Au] Autor:Vasaghi A; Ashraf A; Shirzadi A; Petramfar P
[Ad] Endereço:From the Department of Physical Medicine and Rehabilitation, Shahid Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran (AV, AA, AS); Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran (AV); Shiraz Geriatric Research Center, Shiraz University of Medical Sciences, Shiraz, Iran (AA); and Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran (PP).
[Ti] Título:Case Report of Lewis and Sumner Syndrome with Bilateral Vagus Nerves Paralysis for 16 Years.
[So] Source:Am J Phys Med Rehabil;95(12):e198-e201, 2016 Dec.
[Is] ISSN:1537-7385
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This report describes a patient with dysphonia for 16 years in combination with asymmetric and progressive decrease in sense and power of both upper and lower extremities for the past 3 years. Electrophysiological study revealed asymmetric conduction block and abnormal sensory action potential in 4 limbs. The vagus nerves palsy and abnormal electrodiagnosis of the limbs led us to diagnose the disease as Lewis and Sumner syndrome, also called multifocal acquired demyelinating sensory and motor neuropathy diagnosis, which improved by corticosteroid consumption to some extent. This case is uncommon by its long time presentation and progression. To the best of the authors' knowledge, this is the first report of simultaneous bilateral vagus nerve palsy in combination with upper and lower limbs' demyelinating neuropathy. In conclusion, persistent dysphonia can be a part of the presentation of demyelinating neuropathy.
[Mh] Termos MeSH primário: Polirradiculoneuropatia/diagnóstico
Doenças do Nervo Vago/diagnóstico
[Mh] Termos MeSH secundário: Potenciais de Ação
Adulto
Disfonia/etiologia
Disfonia/fisiopatologia
Eletrodiagnóstico
Seres Humanos
Masculino
Polirradiculoneuropatia/complicações
Síndrome
Doenças do Nervo Vago/complicações
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170717
[Lr] Data última revisão:
170717
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160514
[St] Status:MEDLINE


  9 / 3686 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27084210
[Au] Autor:Kamm C
[Ad] Endereço:Department of Neurology, University of Rostock, Gehlsheimer Str. 20, 18147 Rostock, Germany. Electronic address: christoph.kamm@med.uni-rostock.de.
[Ti] Título:New clinical insights into combined central and peripheral demyelination (CCPD).
[So] Source:J Neurol Sci;364:27-8, 2016 May 15.
[Is] ISSN:1878-5883
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Mh] Termos MeSH primário: Doenças Desmielinizantes
Polirradiculoneuropatia
[Mh] Termos MeSH secundário: Seres Humanos
Polirradiculoneuropatia Desmielinizante Inflamatória Crônica
[Pt] Tipo de publicação:COMMENT; EDITORIAL
[Em] Mês de entrada:1608
[Cu] Atualização por classe:160416
[Lr] Data última revisão:
160416
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160417
[St] Status:MEDLINE


  10 / 3686 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27000248
[Au] Autor:Cortese A; Franciotta D; Alfonsi E; Visigalli N; Zardini E; Diamanti L; Prunetti P; Osera C; Gastaldi M; Berzero G; Pichiecchio A; Piccolo G; Lozza A; Piscosquito G; Salsano E; Ceroni M; Moglia A; Bono G; Pareyson D; Marchioni E
[Ad] Endereço:C. Mondino National Neurological Institute, Pavia, Italy. Electronic address: andrea.cortese@mondino.it.
[Ti] Título:Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment.
[So] Source:J Neurol Sci;363:182-7, 2016 Apr 15.
[Is] ISSN:1878-5883
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Combined central and peripheral demyelination (CCPD) is rare, and current knowledge is based on case reports and small case series. The aim of our study was to describe the clinical features, diagnostic results, treatment and outcomes in a large cohort of patients with CCPD. Thirty-one patients entered this retrospective, observational, two-center study. In 20 patients (65%) CCPD presented, after an infection, as myeloradiculoneuropathy, encephalopathy, cranial neuropathy, length-dependent peripheral neuropathy, or pseudo-Guillain-Barré syndrome. Demyelinating features of peripheral nerve damage fulfilling European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) electrodiagnostic criteria for CIDP were found in 23 patients (74%), and spatial dissemination of demyelinating lesions on brain MRI fulfilling the 2010 McDonald criteria for multiple sclerosis (MS) in 11 (46%). Two thirds of the patients had a relapsing or progressive disease course, usually related to the appearance of new spinal cord lesions or worsening of the peripheral neuropathy, and showed unsatisfactory responses to high-dose corticosteroids and intravenous immunoglobulins. The clinical presentation of CCPD was severe in 22 patients (71%), who were left significantly disabled. Our data suggest that CCPD has heterogeneous features and shows frequent post-infectious onset, primary peripheral nervous system or central nervous system involvement, a monophasic or chronic disease course, inadequate response to treatments, and a generally poor outcome. We therefore conclude that the current diagnostic criteria for MS and CIDP may not fully encompass the spectrum of possible manifestations of CCPD, whose pathogenesis remains largely unknown.
[Mh] Termos MeSH primário: Doenças Desmielinizantes/diagnóstico por imagem
Doenças Desmielinizantes/terapia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Estudos de Coortes
Feminino
Seguimentos
Seres Humanos
Imagem por Ressonância Magnética
Masculino
Meia-Idade
Polirradiculoneuropatia/diagnóstico por imagem
Polirradiculoneuropatia/terapia
Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/diagnóstico por imagem
Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/terapia
Estudos Retrospectivos
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161231
[Lr] Data última revisão:
161231
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160323
[St] Status:MEDLINE



página 1 de 369 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde